5 unknown, 4 completed, 1 not yet recruiting, 1 terminated. 11 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Unknown 5, Completed 4, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 4 | Unknown 2, Completed 1, Not yet recruiting 1 |
Follow SHR3162: new trials by email Literature Review of SHR3162 trials Research Report on SHR3162
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing Serplulimab, Fluzoparib, Topotecan/Irinotecan/Paclitaxel/Temozolomide - SCLC, Extensive Stage | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 100 | 2025-12-31 | 2025-08-26 |
| A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer Fluzoparib - Pancreatic Cancer | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 74 | 2020-12-17 | 2020-12-31 |
| A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC） Fluzoparib, Apatinib - Small Cell Lung Cancer Extensive Stage | Phase 1 / Phase 2 | Unknown | Tianjin Medical University Second Hospital | 53 | 2020-07-01 | 2020-12-09 |
| A Trial of SHR3162 in Healthy Caucasian Volunteers SHR3162 - Healthy Volunteers | Phase 1 | Completed | Atridia Pty Ltd. | 12 | 2020-04-17 | 2022-07-14 |
| Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy Chinese Subjects SHR3162 - Healthy Adult Male and Female Volunteers | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 12 | 2020-04-10 | 2020-04-10 |
| A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer Fluzoparib, Fluzoparib placebo, mFOLFIRINOX - Advanced Pancreatic Cancer | Phase 1 / Phase 2 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 39 | 2020-01-21 | 2024-08-16 |
| FUSCC Refractory TNBC Umbrella (FUTURE) Pyrotinib with Capecitabine, AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4), anti PD-1 with nab-paclitaxel - Triple-negative Breast Cancer | Phase 1 / Phase 2 | Unknown | Fudan University | 140 | 2018-10-18 | 2022-08-10 |
| The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors SHR7390, SHR-1210, SHR3162 - Solid Tumor | Phase 1 | Terminated | Jiangsu HengRui Medicine Co., Ltd. | 31 | 2017-07-24 | 2022-09-01 |
| A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients Fluzoparib, Apatinib - Ovarian Cancer, Triple Negative Breast Cancer | Phase 1 | Completed | Jiangsu HengRui Medicine Co., Ltd. | 98 | 2017-03-09 | 2022-07-01 |
| A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients Fluzoparib, Apatinib, Paclitaxel - Recurrent and Metastatic Gastric Cancer | Phase 1 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 24 | 2017-01-01 | 2017-03-07 |
| A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors SHR3162 - Neoplasm, Solid Tumors | Phase 1 | Completed | Atridia Pty Ltd. | 30 | 2016-06-01 | 2019-09-19 |
Triple Negative Breast Neoplasms (2) · Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Recurrence (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1)
Jiangsu HengRui Medicine Co., Ltd. (6) · Atridia Pty Ltd. (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Fudan University (1) · Tianjin Medical University Second Hospital (1)
China (7) · Australia (2)
Boyong Shen, M.D. (1) · Haitao Wang (1) · RuiHua Xu, MD, PhD (1) · Xianjun Yu, M.D. (1) · Zhimin U Shao, Professor (1)
PMID 32719455, PMID 35105939, PMID 37775744, PMID 38290515, PMID 39232761